Brisbane, CA 1/24/17—Molecular diagnostics firm CareDx has agreed to acquire the Conexio SBT Resolver products and Assign SBT analysis software for HLA typing from Illumina. CareDx provides diagnostic surveillance solutions for transplant recipients. CareDx’s Olerup business previously distributed the products. “The sale of Conexio’s capillary electrophoresis SBT portfolio permits Illumina to focus on next-generation sequencing products for HLA typing,” stated Rob Brainin, vice president and general manager, Applied Genomics at Illumina.

Illumina acquired Conexio last year (see IBO 1/15/16). The SBT (Sequencing Based Typing) Resolver reagents are designed for PCR-based HLA typing for use with Sanger sequencing. In an SEC filing, CareDx disclosed terms of the agreement, including revenue-based quarterly payments to Conexio of up to $735,000.